Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

839
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
839
RNA Interference01:23

RNA Interference

26.2K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Immunomodulator therapies in pandemics: lessons from COVID-19 and a blueprint for future outbreaks.

Expert opinion on biological therapy·2026
Same author

A Targeted Blockade of Terminal C5a Is Critical to Management of Sepsis and Acute Respiratory Distress Syndrome: The Mechanism of Action of Vilobelimab.

International journal of molecular sciences·2025
Same author

Metformin on Time to Sustained Recovery in Adults with COVID-19: The ACTIV-6 Randomized Clinical Trial.

medRxiv : the preprint server for health sciences·2025
Same author

Metformin on the Presence of COVID-19 Symptoms Over 6 Months: The ACTIV-6 Randomized Clinical Trial.

medRxiv : the preprint server for health sciences·2025
Same author

Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.

JAMA·2025

Related Experiment Video

Updated: Jul 31, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.4K

Interferon lambda as a potential treatment for COVID-19.

Matthew W McCarthy1

  • 1Department of Medicine, Weill Cornell Medicine, New York, NY, USA.

Expert Opinion on Biological Therapy
|May 6, 2023
PubMed
Summary

Pegylated interferon lambda significantly lowered hospitalization risks for high-risk COVID-19 patients. This antiviral treatment shows promise in preventing severe outcomes from SARS-CoV-2 infection.

Keywords:
COVID-19InterferonsSARS-CoV-2antiviralcytokinestype III interferons

More Related Videos

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

13.7K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.1K

Related Experiment Videos

Last Updated: Jul 31, 2025

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

13.4K
Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
10:10

Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses

Published on: November 16, 2016

13.7K
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

12.1K

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Interferons are key innate immune signaling molecules crucial for antiviral responses.
  • Exogenous interferon administration is a potential therapeutic strategy to mitigate viral disease progression, including COVID-19.

Purpose of the Study:

  • To evaluate the efficacy of pegylated interferon lambda in preventing severe outcomes in non-hospitalized adult patients with SARS-CoV-2 infection.
  • To review the existing knowledge on interferon lambda's role in COVID-19 treatment, its limitations, and future applications.

Main Methods:

  • Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial.
  • Inclusion of high-risk, non-hospitalized adult patients diagnosed with SARS-CoV-2 infection.
  • Comparison of treatment with pegylated interferon lambda versus placebo.

Main Results:

  • Pegylated interferon lambda substantially reduced the risk of COVID-19-related hospitalizations.
  • A significant decrease in emergency room visits was observed in the treatment group compared to placebo.
  • The study focused on high-risk, non-hospitalized adult patients with SARS-CoV-2 infection.

Conclusions:

  • Pegylated interferon lambda is an effective therapeutic option for reducing severe COVID-19 outcomes in high-risk patients.
  • Interferon lambda represents a promising antiviral strategy for managing SARS-CoV-2 infections.
  • Further research should explore the long-term implications and broader applications of interferon lambda in treating viral diseases.